KalVista Pharmaceuticals (NASDAQ:KALV) and Ionis Pharmaceuticals (NASDAQ:IONS) announced on Friday that the European Commission has granted final approval for two of their treatments targeting rare genetic disorders. Cambridge, Massachusetts-based KalVista (NASDAQ:KALV) said that the EC and Swiss medical regulator, the ...